Dr. Antreas Hindoyan, Amgen, received his PhD at UCLA in molecular and medical pharmacology. He began his industry career as a scientist at Molecular Response LLC working on novel assay development for personalized treatment of solid tumors. He joined Amgen in 2015 as a scientist in the Clinical Biomarkers Lab, leading clinical assay development and validation work to support several early stage oncology assets. He soon transitioned into the global biomarker lead role, where he was accountable for developing the clinical biomarker strategy and execution across multiple early and late Oncology development programs including small molecule (e.g. Sotorasib) and T cell engager (e.g. AMG 330) modalities. In the last two years he has served as a precision medicine lead overseeing cross-functional teams within the Oncology small molecule TA (e.g. AMG 193), integrating biomarker, diagnostic, research and human data plans to enable holistic translational strategies and enhance program value.